RASAL3

Across TCGA pan-cancer cohorts, RASAL3 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated RASAL3 data layer compared with 24 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher RASAL3 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated RASAL3 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LUAD show a favorable association.

CCRCC, LUAD, and PDAC are the cancer types where RASAL3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Quartile	All	0.926	0.633	.003	20	view →
LUAD	DFS	Median	All	0.765	0.519	.005	15	view →
PDAC	OS	Median	III,IV	0.326	0.829	.004	9	view →
HNSC	DFS	Tertile	All	0.918	1.000	.014	8	view →
COAD	DFS	Quartile	III,IV	0.797	1.000	.041	6	view →
LSCC	OS	Quartile	II,III,IV	0.466	0.929	.009	4	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

RASAL3–CCRCC (DFS)

Open the CCRCC breakdown →